Loxapine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Loxapine: From Schizophrenia to Manic Bipolar Affective Disorder
One-Sentence Summary
Loxapine is a first-generation dibenzoxazepine antipsychotic historically used for schizophrenia and other psychotic disorders. The TxGNN model predicts it may be effective for Manic Bipolar Affective Disorder, and while no clinical trials are yet structured into this evidence pack, 20 publications support the direction — several of which reference two pivotal Phase III RCTs of the inhaled formulation (Adasuve) already approved in the US and EU for acute agitation in bipolar disorder.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia / psychotic disorders (established in literature; not present in the German regulatory registry data supplied) |
| Predicted New Indication | Manic Bipolar Affective Disorder |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed, formally structured MOA data from DrugBank is not available in this evidence pack (data gap DG002). Based on well-established pharmacological literature, however, loxapine is a dibenzoxazepine-class first-generation antipsychotic that acts as a dual antagonist at dopamine D2 receptors and serotonin 5-HT2A receptors — the same receptor profile shared by most atypical antipsychotics used across the psychotic-spectrum disorders.
Schizophrenia and bipolar mania are distinct diagnoses but share a common acute clinical problem: psychomotor agitation driven by dopaminergic/serotonergic dysregulation. D2/5-HT2A blockade is the core pharmacological mechanism for controlling this symptom regardless of the underlying primary diagnosis, which is the mechanistic bridge underlying this prediction.
Critically, this is not a purely novel hypothesis — the inhaled loxapine formulation (Adasuve, Staccato delivery system) is already approved in the US and EU specifically for acute agitation in both schizophrenia and bipolar I disorder, based on two pivotal Phase III RCTs (NCT00628589, NCT00721955) plus the head-to-head PLACID trial versus IM aripiprazole. This TxGNN prediction therefore represents a label-adjacent indication extension with strong real-world clinical precedent, rather than a speculative new mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered in this evidence pack's structured clinical_trials field.
Note: The literature evidence below references two named pivotal Phase III RCTs (NCT00628589, NCT00721955) and the PLACID trial as the basis for the existing US/EU approval of inhaled loxapine in bipolar agitation. These should be pulled into a structured trial registry entry as a priority remediation item.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29724638 | 2018 | RCT | Eur Neuropsychopharmacol | PLACID trial: inhaled loxapine vs. IM aripiprazole in acutely agitated schizophrenia/bipolar I patients across 23 centres (Czech Republic, Germany, Spain, Russia) |
| 29163985 | 2017 | RCT (post-hoc analysis) | BJPsych Open | PANSS-EC responder analysis from two pivotal Phase III RCTs (NCT00628589, NCT00721955) in 344 schizophrenia and 314 bipolar I patients |
| 22226343 | 2012 | RCT (effect-size analysis) | Int J Clin Pract | Effect-size re-analysis of inhaled loxapine efficacy from 2 Phase III RCTs in schizophrenia/bipolar disorder |
| 27151529 | 2016 | Systematic Review / Meta-analysis | Hum Psychopharmacol | Systematic review and meta-analysis of pharmacologic agitation treatments in schizophrenia and bipolar disorder |
| 23740380 | 2013 | Review | CNS Drugs | Review of inhaled loxapine powder (Adasuve), approved in US/EU for acute agitation in bipolar disorder/schizophrenia; median Tmax ~2 min |
| 30721526 | 2019 | Expert Review/Consensus | Drugs in R&D | Expert commentary on inhaled loxapine for acute agitation management in bipolar disorder and schizophrenia |
| 27121764 | 2016 | Review (incl. Phase 3 RCT summary) | Curr Med Res Opin | Review of urgent treatment efficacy/safety of inhaled loxapine, summarizing Phase 3 evidence |
| 31496709 | 2019 | Review | Neuropsychiatr Dis Treat | Safety, efficacy, and patient-acceptability review of inhaled loxapine in bipolar I disorder/schizophrenia agitation |
| 28376877 | 2017 | RCT design paper | BMC Psychiatry | Rationale and design of the PLACID RCT comparing inhaled loxapine vs. IM aripiprazole |
| 37581475 | 2023 | Review | Expert Opin Pharmacother | Review on improving pharmacotherapy of agitation associated with bipolar disorder, including loxapine |
Germany Market Information
Loxapine is currently not marketed in Germany (0 authorizations on record in the evidence pack). No product license table is available at this time.
Safety Considerations
Please refer to the package insert for safety information.
Note:
key_warnings,contraindications, and drug interaction data are all flagged as data gaps in this evidence pack (DG001, severity: Blocking). This gap currently prevents entry into the S1 safety pre-screening stage and must be resolved before further progression.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale:
- The mechanistic rationale is strong and the evidence level is L1 — inhaled loxapine already carries regulatory approval in the US and EU for acute agitation in bipolar I disorder, supported by two pivotal Phase III RCTs and a head-to-head trial (PLACID). This makes the prediction a near-label extension rather than a speculative hypothesis.
- However, the drug is not currently marketed in Germany and safety/contraindication data is a Blocking gap, so the recommendation cannot advance to full Go status without remediation.
To proceed, the following is needed:
- TFDA/German-market package insert warnings and contraindications (DG001 — Blocking; required before S1 safety pre-screening)
- Formal DrugBank MOA record (DG002 — High priority)
- Structured entry of the two pivotal Phase III trials (NCT00628589, NCT00721955) and the PLACID trial into the clinical trial evidence registry
- Route compatibility assessment — the approved indication relies on the inhaled Staccato delivery device (Adasuve); confirm whether this specific formulation, not just oral loxapine, is the intended repurposing candidate
- Regulatory pathway assessment for market entry, given zero existing authorizations in Germany
Note: Ranks 2–10 of the predicted indications for this drug (retinal dystrophy, hydranencephaly, X-linked myopia variants, congenital glycosylation disorder, CMT type 1G, polymicrogyria syndrome, syndromic myopia, atypical glycine encephalopathy) were all scored L5 / Hold — no supporting literature or trials, and no plausible pharmacological link to loxapine's D2/5-HT2A mechanism. These are assessed as knowledge-graph embedding noise (likely driven by a shared rare-disease/ophthalmologic co-occurrence cluster) and require no further action at this time.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.